MX341873B - Formulaciones solidas de retardo basadas en dispersiones solidas. - Google Patents

Formulaciones solidas de retardo basadas en dispersiones solidas.

Info

Publication number
MX341873B
MX341873B MX2013007335A MX2013007335A MX341873B MX 341873 B MX341873 B MX 341873B MX 2013007335 A MX2013007335 A MX 2013007335A MX 2013007335 A MX2013007335 A MX 2013007335A MX 341873 B MX341873 B MX 341873B
Authority
MX
Mexico
Prior art keywords
solid
formulations based
dispersions
retard formulations
formulation
Prior art date
Application number
MX2013007335A
Other languages
English (en)
Other versions
MX2013007335A (es
Inventor
Liepold Bernd
Berndl Gunther
Lander Ute
Weis Juergen
Granzow Dietrich
Westedt Ulrich
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2013007335A publication Critical patent/MX2013007335A/es
Publication of MX341873B publication Critical patent/MX341873B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Abstract

La presente invención se refiere a una formulación que comprende un producto de dispersión sólida procesado en estado fundido, que comprende un agente activo, un polímero termoplástico de N-vinil-lactama farmacéuticamente aceptable, y un copolímero de injerto de alcohol polivinílico - polialquilenglicol, farmacéuticamente aceptable. Un método de producción de dicha formulación.
MX2013007335A 2010-12-23 2011-12-22 Formulaciones solidas de retardo basadas en dispersiones solidas. MX341873B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10196936 2010-12-23
PCT/EP2011/073850 WO2012085236A1 (en) 2010-12-23 2011-12-22 Solid retard formulations based on solid dispersions

Publications (2)

Publication Number Publication Date
MX2013007335A MX2013007335A (es) 2014-03-05
MX341873B true MX341873B (es) 2016-09-06

Family

ID=44063216

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007335A MX341873B (es) 2010-12-23 2011-12-22 Formulaciones solidas de retardo basadas en dispersiones solidas.

Country Status (15)

Country Link
US (1) US10463739B2 (es)
EP (1) EP2654731B1 (es)
JP (1) JP5903686B2 (es)
CN (1) CN103260609B (es)
CA (1) CA2821659C (es)
DK (1) DK2654731T3 (es)
ES (1) ES2598235T3 (es)
HK (1) HK1189834A1 (es)
MX (1) MX341873B (es)
PL (1) PL2654731T3 (es)
PT (1) PT2654731T (es)
RU (1) RU2013134339A (es)
SG (1) SG191316A1 (es)
WO (1) WO2012085236A1 (es)
ZA (1) ZA201304487B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114170B2 (en) 2012-11-08 2015-08-25 Isp Investments Inc. Highly loaded amorphous efavirenz composition and process for preparing the same
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10561142B2 (en) * 2015-08-20 2020-02-18 Conopco, Inc. Dispersed lactams
CN117338617A (zh) 2015-08-20 2024-01-05 联合利华知识产权控股有限公司 改善的内酰胺溶解度
CN107920978A (zh) 2015-08-20 2018-04-17 荷兰联合利华有限公司 改善的内酰胺溶解度
CN108024939A (zh) 2015-08-20 2018-05-11 荷兰联合利华有限公司 包封的内酰胺
BR112018003182B1 (pt) 2015-08-20 2021-07-13 Unilever Ip Holdings B.V. Composição que compreende lactama e tensoativo não iônico
US20190175589A1 (en) * 2017-11-09 2019-06-13 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
CN112263567B (zh) * 2020-10-19 2022-05-03 南京易亨制药有限公司 一种布洛芬缓释胶囊及制备方法
AU2022229953A1 (en) * 2021-03-04 2023-09-07 Reckitt Benckiser Health Limited Novel composition
JP2024511653A (ja) * 2021-04-01 2024-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低溶解性医薬の連続加熱溶融造粒のためのプロセス

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1077430B (de) 1958-04-15 1960-03-10 Hoechst Ag Verfahren zur Herstellung von Pfropfpolymerisaten von Polyvinylestern
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3536530A1 (de) 1985-10-12 1987-04-23 Basf Ag Verwendung von pfropfcopolymerisaten aus polyalkylenoxiden und vinylacetat als vergrauungsinhibitoren beim waschen und nachbehandeln von synthesefasern enthaltendem textilgut
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
JP4284199B2 (ja) * 2004-01-26 2009-06-24 株式会社日立コミュニケーションテクノロジー 光クロスコネクト装置及び網管理装置
CA2612864A1 (en) * 2005-07-05 2007-01-11 Abbott Gmbh & Co. Kg Composition and dosage form comprising a solid or semi-solid matrix
ES2427724T3 (es) * 2006-02-03 2013-10-31 Evonik Röhm Gmbh Composiciones farmacéuticas, que contienen mezclas de polímeros y de sustancias activas difícilmente solubles en agua
EP1832281A1 (en) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
CL2008003092A1 (es) * 2007-10-19 2009-11-27 Abbott Gmbh & Co Kg Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
CN102458368B (zh) 2009-05-13 2014-02-26 巴斯夫欧洲公司 含有基于聚醚的共聚物与微水溶性聚合物组合的固体药物制剂

Also Published As

Publication number Publication date
EP2654731A1 (en) 2013-10-30
WO2012085236A1 (en) 2012-06-28
JP5903686B2 (ja) 2016-04-13
EP2654731B1 (en) 2016-07-27
HK1189834A1 (zh) 2014-06-20
SG191316A1 (en) 2013-07-31
CA2821659A1 (en) 2012-06-28
ZA201304487B (en) 2014-03-26
CN103260609A (zh) 2013-08-21
CN103260609B (zh) 2017-08-11
US10463739B2 (en) 2019-11-05
CA2821659C (en) 2019-05-14
RU2013134339A (ru) 2015-01-27
US20140296336A1 (en) 2014-10-02
JP2014500299A (ja) 2014-01-09
DK2654731T3 (en) 2016-11-14
MX2013007335A (es) 2014-03-05
ES2598235T3 (es) 2017-01-26
PT2654731T (pt) 2016-11-07
PL2654731T3 (pl) 2017-01-31

Similar Documents

Publication Publication Date Title
MX341873B (es) Formulaciones solidas de retardo basadas en dispersiones solidas.
MX2010009043A (es) Composicion farmaceutica para farmacos poco solubles.
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
MX2014011815A (es) Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
WO2011057224A3 (en) Zwitterionic polymer bioconjugates and related methods
MY156888A (en) Solid Compositions
WO2009129503A3 (en) Block copolymer comprising at least one polyester block and a poly(ethylene glycol) block
MX2012014384A (es) Composiciones solidas.
GB2497011A (en) Ophthalmic device molds and related methods
MX2013001493A (es) Composiciones orales que comprenden un compuesto de cinc y un agente anti-microbiano.
MX2014008008A (es) Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
WO2008005897A3 (en) System and method for operating a mobile device, such as providing an out of box connection system for uma type mobile devices
WO2011084620A3 (en) Particles for multiple agent delivery
WO2012048102A3 (en) Systems and methods for magnetically charging and discharging a member configured for medical use
TN2013000267A1 (en) Biodegradable drug delivery compositions
EP2590432A4 (en) Conversation detection device, hearing aid and conversation detection method
HK1172845A1 (en) Novel pharmaceutical formulations against drug misuse
MX354416B (es) Formulaciones a base de nalbufina y sus usos.
MY175387A (en) Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same
AU2018256608A1 (en) Slow-release conjugates of SN-38
WO2012087327A3 (en) Polymer systems
WO2011108826A3 (en) Complex formulation for oral administration comprising probiotic formulation and 5-ht4 receptor agonist and method for the preparation thereof
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
WO2012092486A3 (en) Modified release benzimidazole formulations
NZ628395A (en) Formulations containing trametinib dimethyl sulfoxide

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE DEUTSCHLAND GMBH & CO. KG.

FG Grant or registration